Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Some extracts from the Cohen Report

"His canned response has been that he's not even considering it"

You may read RG's shareholderletter again:

"There is no discussion to pursue a reverse split under the current market conditions, however, I have begun dialogue with the Board about the conditions, both internal and external, which would serve as a trigger to launch the process."

There is a thin line between the discussion to PURSUE a RS and the beginning of the dialogue about the conditions.

The question remains: how long will this dialogue last until it becomes a discussion?

GLTY





Share
New Message
Please login to post a reply